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Myasthenia Gravis: A closer look
Erin L. Ricker, BSN, RN
Otterbein University, Westerville, Ohio
Introduction
Myasthenia gravis (MG) is a rare,
chronic autoimmune disease that affects
the neurotransmitter acetylcholine and the
acetylcholine receptors at the
neuromuscular junction (Mestecky, 2013).
MG causes fluctuating skeletal muscle
weakness and fatigue. According to the
Myasthenia Gravis Foundation of America
(MGFA) (2010), 20 per 100,000 patients
are diagnosed with MG, although
researchers believe several more patients
are misdiagnosed or missed entirely.
Several neurological disorders have
similar clinical presentations to MG making
it difficult for inexperienced practitioners
to identify and properly diagnose patients.
Patients are often misdiagnosed and
delayed proper treatment for one to two
years after initial presentation of
symptoms (Koch, Steele, & Koch, 2013).
Remissions and exacerbations make MG
difficult for practitioners to diagnose
(Weeks, 2012).
Other possible differential diagnoses
include:
•
Guillian Barré
•
Bell’s palsy
•
Multiple Sclerosis
•
Amyotrophic lateral sclerosis
•
Polymyositis
•
Stroke
As an Advanced Practice Nurse (APN), it
is important to understand the variable
clinical presentations that can occur with
this disease. The purpose of this
presentation is to discuss an individual
case study and review the pathophysiology
of MG in order to assist the APN in
recognizing symptoms early.

Clinical Features
Case Study Cont’d
The patient was sent for an immediate
magnetic resonance image (MRI) with
suspicions of an aneurysm or stroke.
Results of the MRI were normal. The
patient was then referred to a
neurologist for additional testing. After
an ophthalmic catheterization to rule out
blockages and several neurological
examinations, results were inconclusive.
A tensilon test was performed to confirm
suspicions of MG. Following the positive
tensilon test, the patient was checked for
acetylcholine receptor antibodies (AChRAbs) which were present in the patient’s
blood serum. AChR-Abs are detected in
approximately 50% of patients with
ocular MG, although AChR-Abs are
present in 80-90% of patients with
generalized MG (Azeem, Law, & Arora,
2014).

•
•

•
•

•
•
(Muscular Dystrophy Association, 2014)

Epidemiology
•
•

•
•

•

Case Study
A 59-year-old Caucasian male was seen
by his primary care provider (PCP) with
complaints of blurred vision and increased
difficulty raising his eyelids. Upon further
evaluation, the PCP learned the patient had
recently returned home from a one week
long trip to Utah. While in Utah, the patient
stated he developed a bad cold with
symptoms of extremely sensitive, watery
eyes and severe headaches. Symptoms
progressed throughout the week with
continued complaints of double vision and
weakness in raising bilateral eyelids.
Weakness was noted in both eyes, although
the patient stated his right eye was worse
than the left eye. Upon returning home, the
patient was first seen by his optometrist who
recommended further evaluation by his
primary care provider (PCP).

•

•

•

MG occurs in all races and affects both
males and females (MGFA, 2010).
Asians, compared to other ethnic
groups, have a slightly more common
onset of MG at a younger age (Weeks,
2012).
MG can occur at any age although
most patient affected are over fifty
years of age (Abbott, 2010).
Women are often affected more than
men during the first five decades,
where as men are more commonly
affected between the sixth and eighth
decade (Koch et al., 2013).
Approximately 20,000 to 70,000
people in the United States are
affected by MG (McCance, Huether,
Brashers, & Rote, 2014).
Advances in treatment options such as
plasmapheresis, immune therapy, and
thymectomy are believed to have
increased patient’s longevity (Abbott,
2010).
Although MG is not hereditary, 5% of
cases show a familial predisposition
for acquiring the disease (Weeks,
2012).

(Mestecky, A., 2013, p.111)

Pathophysiology
MG is an autoimmune disease caused
by autoantibodies that target skeletal
muscles (Cufi et al., 2012). Researchers
believe a virus or bacteria is responsible
for triggering the body’s autoimmune
response (Weeks, 2012). Once the
immune system is triggered, activated B
cells, or plasma cells, begin producing
immunoglobulin G (IgG). Synthesis of
anti-AChR antibodies require activated
CD4+ T cells to interact with and
stimulate B cells (Cufi et al., 2012). The
thymus gland, suspected in developing
autoantibodies that block receptor sites
for acetylcholine (ACh), stores T cells and
is a common target organ for infectious
diseases. (Cufi et al., 2012).
ACh is a neurotransmitter responsible
for producing voluntary muscle
contraction. Voluntary muscles are
controlled by nerve impulses sent from
the brain to motor neurons that stimulate
one or more muscle cells within the
neuromuscular junction (NMJ) (McCance,
et al., 2014).

NMJs are formed as axons divide and
enter skeletal muscles (Weeks, 2012).
When stimulated, ACh is released from the
axons (Weeks, 2012). Voluntary skeletal
muscle contractions occurs from the
binding of ACh to the nicotinic
acetylcholine receptors (AChR) (Mestecky,
2013). The NMJ also consists of a synaptic
cleft which contains acetylcholinesterase
(AChE), an enzyme responsible to
hydrolyze ACh and terminate signal
transmission (Trouth, Dabi, Solieman,
Kurukumbi, & Kalyanam, 2012).
Anti-AChR antibodies affect
neuromuscular transmission through
complement binding and activation,
antigenic modulation, or complete
blockage of the AChR (Cufi et al., 2012).
This blockage causes a defect in nerve
impulse transmission at the NMJ (McCance
et al., 2014). Over time, functional loss of
AChRs occurs and affected muscles
become inadequately stimulated resulting
in weakness and fatigability (Mestecky,
2013). Antibodies destroy receptor sites
faster than the body can replace them,
reducing receptor sites by approximately
80% (MGFA, 2010).
Generally patients over 50 years of age
have normal or atrophic thymus glands
(Koch et al., 2013). Approximately 70% of
patients with MG continue to produce
antibodies as a result of thymus
hyperplasia or tumors, called thymomas
(Weeks, 2012).

•
Thymomas are usually benign, thymic
epithelial tumors. Approximately 30-50%
of patients with thymomas develop MG
(Priola & Priola, 2014). Thymectomy is
generally recommended for patients with
thymoma and reduces symptoms in
approximately 70% of patients (Weeks,
2012). The patient presented in this case
study later discovered he did not have a
thymoma. Koch et al. (2013) recommend
all patients with MG have a computed
tomography or magnetic resonance
imaging to detect presence of thymomas.
In addition to those who produce AChR
antibodies, two other subtypes of MG exist:
seronegative-MG and muscle-specific
tyrosine kinase (MuSK) MG (Mestecky,
2013). No antibodies are identified in
patients with seronegative-MG. Patients
with MuSK-MG produce antibodies that
attack a different protein, the musclespecific tyrosine kinase, in the NMJ
(Mestecky, 2013).

•
•
•

•

•

There are two main clinical categories
of MG: generalized AChR myasthenia
and ocular myasthenia.
Ocular myasthenia symptoms are
limited to the eyelids and extraocular
muscles (Azeem et al., 2014).
Generalized AChR myasthenia includes
generalized symptoms in which
bulbar, limb, and respiratory muscles
are affected (Azeem et al., 2014).
Patients who experience generalized
symptoms typically present with
ocular symptoms first (Weeks, 2012).
Fluctuating muscle weakness in
ocular, bulbar, respiratory, and limb
muscles is a hallmark sign of MG
(Khan & Bennett, 2014).
Muscle weakness is often less in the
morning when ACh stores are highest
(Abbott, 2010).
Emotional stress, heat, infections,
surgery, and hyperthyroidism can
exacerbate symptoms and cause
muscle fatigue (Koch et al., 2013).
In the majority of patients, initial
presentations of ptosis and diplopia
are the primary symptoms (Koch et al.,
2013).
Ptosis and diplopia occur from
extraocular muscle (EOM) weakness.
Other common presentations include
slurred speech, dysphagia, dysarthria
and limb weakness (MGFA, 2010).
Muscle weakness is typically
exacerbated with prolonged or
provoked muscle use and improves
with periods of rest (Abbott, 2010).
Detailed review of systems is
imperative to uncover symptoms
patients may believe are insignificant,
such as decreased weakness in the
evening or after strenuous activities
(Abbott, 2010).
Include muscle strength testing and
attempt to provoke muscle fatigue by
asking patients to maintain an upward
gaze. Fluctuating muscle strength is
commonly seen in the ocular and
oropharyngeal muscles (Abbott,
2010).

Common Signs and Symptoms

(Drachman, 2007, p.1)

•

Ptosis (most common early sign)

•

Blurred or double vision

•

Slurred speech

•

Difficulty chewing or swallowing

•

Weakness and fatigue in arms and legs

•

Respiratory weakness

Implications
APNs must recognize symptoms of MG
early to begin proper treatment. As seen in
this case study, symptoms of MG are
variable making MG difficult to diagnose.
The patient developed ocular symptoms
rapidly without fluctuations in muscle
weakness. Typically MG is gradual with
periods of exacerbation and remission.
Patients generally experience increased
muscle fatigue in the evening, unlike the
patient in the case study. The patient
stated he experienced heightened muscle
fatigue often in the morning and at
different times throughout the day. The
patient’s MG was believed to be triggered
by a virus causing the body to produce
anti-AChR antibodies that began blocking
receptors in the extraocular muscles. The
patient’s case is also rare in that clinical
presentation was limited to ocular
symptoms and did not progress to other
skeletal muscles. According to Koch et al.
(2013), only 10% to 40% of symptoms are
limited to extraocular muscles (EOMs).
Because the patient sought medical
assistance rapidly and physicians were
able to confirm a diagnosis of MG, the
patient was treated properly and overall
outcomes were improved. It is unknown
whether symptoms would have progressed
beyond the EOMs if diagnosis and
treatment were delayed.

Conclusion
As seen in this case study, MG can have
presentations similar to other
neurological diseases. Because MG is
relatively rare with variable clinical
presentations, it is important for the APN
to understand the subtypes and
characteristics. To avoid misdiagnosis,
APNs should consider MG when patients
report fluctuating muscle weakness
(Abbott, 2010). Understanding variations
of MG can assist the APN in confirming a
diagnosis and avoid delays in treatment
(Koch et al., 2013). A thorough review of
symptoms along with a complete physical
and neurological examination is vital to
diagnose MG. MG should also be included
in the differential diagnosis for any
patient who reports fluctuating muscle
weakness and complaints of ophthalmic,
neurologic, or gastrointestinal issues
(Abbott, 2010). Although there is
currently no cure for MG, recognizing
symptoms early can improve patient
outcomes. Early diagnosis and treatment
can improve patient outcomes and
decrease disease progression. With
proper treatment, patients with MG can
lead relatively normal lives.
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